University of Vermont

College of Arts and Sciences

Department of Psychological Science

Stacey Sigmon

Human Behavioral Pharmacology

Stacey Sigmon

Stacey Sigmon
Research Associate Professor of Psychiatry
Research Associate Professor of Psychological Science

Education
  • B.A. University of North Carolina at Chapel Hill, 1995
  • M.A. University of Vermont, 1999
  • Ph.D. University of Vermont, 2002
C.V. (PDF)
Email: stacey.sigmon@uvm.edu
Phone: (802) 656-8714
Room: FAHC-UHC Room 1415

Directorships
Director, The Chittenden Clinic

Duties
Faculty, Substance Abuse Treatment Center
Faculty, Human Behavioral Pharmacology Laboratory
Faculty, Behavioral Pharmacology of Drug Dependence Training Program

Areas
Behavioral and pharmacological treatment of opioid dependence; Novel formulations of pharmacotherapies for opioid dependence; Smoking cessation among opioid-dependent patients using a behavioral approach; Laboratory models for understanding the interactions between stimulant medications, including nicotine, cocaine, d-amphetamine and methylphenidate; Behavioral treatments of substance use/abuse among individuals with serious mental illness.

Facilities

Vermont Center on Behavior and Health: The Vermont Center on Behavior and Health (VCBH) is an interdisciplinary center of research excellence committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death.

Human Behavioral Pharmacology Laboratory (HBPL): This facility of 6,000 sq. ft., is located adjacent to the University of Vermont (UVM) campus in Burlington and is the site for laboratory research in drug self-administration, drug discrimination, and the direct effects of drugs and for treatment studies for smoking cessation.

Substance Abuse Treatment Center (SATC): This facility of 2,900 sq. ft., is also located adjacent to the UVM campus, and is our site for the development and testing of scientifically-based behavioral and pharmacological treatments for cocaine and opioid dependence as well as smoking cessation for pregnant women. For addtional information on the Substance Abuse Treatment Center3.

Representative Publications

  • Sigmon, S.C. (in press). Interim treatment: Bridging delays to opioid treatment access. Preventive Medicine.
  • Sigmon, S.C. (2015). The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2014.2421.
  • Sigmon, S.C. (2014). Access to treatment for opioid dependence in rural America: Challenges and future directions. JAMA Psychiatry, 71(4), 359-60.
  • Sigmon, S.C., Dunn, K., Saulsgiver, K., Patrick, M., Badger, G.J., Heil, S.H., Brooklyn, J., & Higgins, S.T. (2013). A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry, 70(12), 1347-1354.
  • Rosenthal, R.N., Ling, W., Casadonte, P., Vocci, F., Bailey, G.L., Kampman, K., Patkar, A., Chavoustie, S., Blasey, C., Sigmon, S.C., & Beebe, K.L. (2013). Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction, 108(12), 2141-2149.
  • Sigmon, S.C., Bisaga, A., Nunes, E.V., O’Connor, P., Kosten, T. & Woody, G. (2012). Opioid detoxification and naltrexone induction strategies: Recommendations for clinical practice. American Journal of Drug and Alcohol Abuse, 38(3), 187-99.
  • Sigmon, S.C., & Patrick, M.E. (2012). The use of financial incentives in promoting smoking cessation. Preventive Medicine, 55, 24-32.
Chair
Clinical Training Program Director
General/Experimental Program Director
Undergraduate Director
Business Manager
Biobehavioral
Clinical
Developmental
Social
Behavioral Pharmacology
Joint Appointment
Behavior Therapy and Psychotherapy Faculty
Clinical Psychology Internship Program (CPIP)
Post-Doctoral Fellows
Emeriti Faculty
Lecturers
Research/Adjunct
Contact UVM © 2015 The University of Vermont - Burlington, VT 05405 - (802) 656-3131